Assoc Dir, Acute Therapies - OST

Your role at Vantive

The Global Associate Director, Immune Dysregulation & Acute Liver Failure Therapies & Products is responsible for helping shape global strategy and leading execution to accelerate growth across Vantive’s current on-market and future new product development portfolio within Immune Dysregulation and Acute Liver Failure.

What you'll be doing

• Partner with the Sr. Director on strategy development and own execution of the annual operating plan for the Immune Dysregulation and Acute Liver Failure therapies and products portfolio, translating strategic priorities across current on-market and future NPD offerings into measurable growth objectives and workplans.
• Develop business cases and strategic recommendations to determine priority markets, expansion sequencing, and the right archetype footprint models for the therapies and products in scope, balancing market attractiveness, evidence readiness, access potential, resource requirements, and long-term value creation.
• Identify adoption barriers by segment (clinical pathway, workflow, protocol inclusion, training, economic value, procurement, competitive alternatives) and implement targeted interventions to unlock penetration.
• Own and maintain a global lifecycle roadmap aligned to portfolio strategy by sequencing evidence, market access, pricing, education, commercialization, and launch-readiness initiatives across commercialized therapies and future pipeline/NPD products to expand footprint and utilization over time.
• Develop and support portfolio positioning, value proposition architecture, and core messaging across Immune Dysregulation and Acute Liver Failure therapies and products that are clinically credible and economically defensible, enabling a consistent global narrative with local adaptability.
• Coordinate cross-functional execution across functions to align priorities, manage dependencies, and ensure disciplined delivery against timelines, deliverables, and budget.
• Partner with regional and country counterparts to co-develop country growth plans that reflect differences in installed base, clinical practice patterns, tendering/procurement dynamics, and reimbursement pathways.
• Own governance for portfolio performance (KPIs, leading indicators, pipeline of initiatives, risk register) and drive corrective actions when adoption or profitability deviates from plan, escalating key decisions as appropriate.
• Identify and evaluate high-value expansion opportunities (new indications/labels where appropriate, new care settings, channel/partner options, geographic expansion) and collaborate with BD&L on execution.

Portfolio Market Development, Evidence & Reimbursement

• Partner on the design and execution of integrated evidence generation plans for on-market therapies and future NPD programs (clinical, real-world evidence/registries, health economics, and outcomes research) that address the highest adoption, access, and launch barriers across Immune Dysregulation and Acute Liver Failure.
• Partner with Medical Affairs and Clinical to prioritize studies, publications, congress strategy, and KOL engagement plans that strengthen clinical credibility and accelerate protocol inclusion.
• Partner with HEOR/Market Access and regions to support a global reimbursement and value dossier roadmap (claims, endpoints, economic models, budget impact tools) that enables country-specific access strategies.
• Drive barrier-removal initiatives across the adoption funnel: disease/therapy awareness, patient identification and pathway integration, education and competency building, and institutional protocol development.
• Develop global playbooks and toolkits for clinical education (in-person and digital) that regions can localize while preserving scientific accuracy, regulatory compliance, and brand consistency.
• Collaborate with external societies and internal stakeholders to support inclusion in relevant guidelines, pathways, and hospital protocols where appropriate and evidence-supported.

Global Commercialization, Launch Readiness & Pricing

• Support the global go-to-market and launch-readiness framework for current and future therapies and products, including segmentation, positioning, core messages, evidence translation, and adoption pathways aligned to regional and country execution models.
• Support portfolio performance management across countries with different footprints, helping identify the right growth levers by market (pricing, contracting/tenders, channel strategy, training, protocol inclusion, KOL activation, and service model).
• Partner on global pricing and value optimization strategy with regions, Finance, and Market Access—helping establish guardrails, value-based narratives, and decision support to balance growth and profitability.
• Support portfolio investment planning and budget management, ensuring resources are directed to the highest-impact evidence, access, and adoption initiatives with clear ROI hypotheses.

Portfolio Expansion & Implementation

• Build scalable implementation playbooks that translate evidence into practical adoption for Immune Dysregulation and Acute Liver Failure therapies and products, including patient identification, workflow integration, training pathways, protocol templates, launch readiness, and success metrics.
• Coordinate cross-functional readiness for geographic expansion and footprint growth, including supply planning, service model alignment, labeling/claims alignment, and country launch sequencing for on-market products.
• Drive post-implementation learning loops with regions and countries to codify best practices, address variability in ICU practice patterns, and improve adoption velocity over time.

Omnichannel Marketing & Education

• Drive post-implementation learning loops with regions and countries to codify best practices, address variability in ICU practice patterns, and improve adoption velocity over time.

People Leader & Matrix Operating Model

• Lead and develop a small global team (1 direct report) with clear priorities, high standards, and strong coaching, while setting the operating tempo for disciplined execution across the broader matrix.
• Establish a pragmatic operating rhythm (quarterly planning, monthly performance reviews, cross-functional workstream cadences) to drive alignment and accountability across the matrix.
• Influence without authority by aligning stakeholders on shared outcomes, clarifying tradeoffs, and resolving conflicts across functions, regions, and countries.
• Build and maintain strong relationships with KOLs, clinical champions, health economists, and industry partners to enhance credibility and accelerate adoption.
• Model a “strategy + sleeves rolled up” leadership style—balancing high-level direction with hands-on contribution to critical deliverables in a lean team environment.